Search for content, post, videos

Pila Pharma announces new data

Dorte X Gram
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is a highly selective and very potent TRPV1 antagonist, previously in development by Bayer Healthcare and Xent
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.